Ernexa director granted options on 5,083 shares
Subject to continued service, David Polinsky’s 5,083 option grant from ERNA vests 100% on Dec. 31, 2026.
Rhea-AI Filing Summary
Ernexa Therapeutics Inc. (ERNA) reported that director David Polinsky received a grant of stock options covering 5,083 shares of common stock. The options have an exercise price of $4.57 per share, were granted in lieu of prorated director cash compensation for 2026 under the company’s 2026 Omnibus Equity Incentive Plan, and expire on August 31, 2036. Subject to continued service, 100% of the options vest on December 31, 2026, and Polinsky’s total holdings of this option grant are 5,083 options following the reported transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 5,083 shares
Grant/Award
1 txn
Insider
Polinsky David
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) F1 | 5,083 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to buy) — 5,083 contracts (Direct)
Footnotes (1)
- F1. Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.
Key Figures
Stock options granted: 5,083 options
Exercise price: $4.57 per share
Transaction price per share: $0.00 per option
+3 more
6 metrics
Stock options granted
5,083 options
Number of stock options granted to director David Polinsky on 2026-08-31
Exercise price
$4.57 per share
Conversion or exercise price for the stock options granted on 2026-08-31
Transaction price per share
$0.00 per option
Indicates the options were granted at no cost as compensation
Underlying common shares
5,083 shares
Common stock underlying the stock options granted to David Polinsky
Vesting date
December 31, 2026
Date when 100% of the options vest, subject to continued service
Expiration date
August 31, 2036
Expiration date of the stock options granted
Key Terms
Stock Option, Director's Compensation Plan, Omnibus Equity Incentive Plan, vest
4 terms
Stock Option financial
"Represents options to purchase shares of the registrant's common stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Director's Compensation Plan financial
"in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan"
Omnibus Equity Incentive Plan financial
"granted under the Issuer's 2026 Omnibus Equity Incentive Plan"
A single, company-wide plan that lets a business grant different kinds of stock-based pay — such as stock options, shares that vest over time, or other equity awards — to employees, directors and consultants. It matters to investors because it determines how much of the company can be paid out in shares, how quickly those shares enter the market, and how well employees are motivated to grow the business; think of it as a toolbox or menu for paying with ownership stakes that can dilute existing holders and affect company performance.
vest financial
"Subject to continued service, 100% of the stock options will vest on December 31, 2026"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What insider transaction did ERNA director David Polinsky report on this Form 4?
David Polinsky reported an option grant for 5,083 shares of Ernexa Therapeutics Inc. common stock. The options were granted as compensation in stock options instead of prorated director cash compensation for 2026, under the company’s 2026 Omnibus Equity Incentive Plan.
What is the exercise price of the stock options granted to David Polinsky at ERNA?
The stock options granted to David Polinsky have an exercise (conversion) price of $4.57 per share. This is the price at which he may purchase Ernexa Therapeutics Inc. common shares upon exercising the options.
When do David Polinsky’s ERNA stock options vest and expire?
Subject to continued service, 100% of the stock options vest on December 31, 2026. The options have an expiration date of August 31, 2036, after which any unexercised options will lapse.
How many ERNA options does David Polinsky hold after this reported transaction?
After this reported transaction, David Polinsky holds 5,083 stock options covering 5,083 shares of Ernexa Therapeutics Inc. common stock related to this grant, as indicated by the total shares following the transaction field.
Was the ERNA option grant to David Polinsky part of a cashless or paid transaction?
The Form 4 reports a transaction price per share of $0.00 for the grant, meaning the options were awarded as compensation rather than purchased for cash. The $4.57 figure is the exercise price payable if and when the options are exercised.
Is the ERNA option grant to David Polinsky under a specific compensation plan?
Yes. The options were granted in lieu of prorated director’s cash compensation for 2026 pursuant to the Director’s Compensation Plan effective August 15, 2026, and were granted under Ernexa Therapeutics Inc.’s 2026 Omnibus Equity Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
